Q1 Earnings Estimate for TNYA Issued By HC Wainwright

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Tenaya Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.59) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at ($0.58) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04.

A number of other equities analysts have also weighed in on TNYA. Canaccord Genuity Group dropped their target price on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday. Chardan Capital lowered their price objective on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Morgan Stanley lowered their price objective on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus price target of $6.25.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ:TNYA opened at $0.70 on Thursday. The firm has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.82. Tenaya Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $5.39. The firm has a market cap of $55.37 million, a price-to-earnings ratio of -0.49 and a beta of 2.83.

Insider Buying and Selling at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of the stock in a transaction on Wednesday, March 5th. The stock was acquired at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the transaction, the insider now directly owns 49,313,559 shares of the company’s stock, valued at $34,519,491.30. This trade represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 19,621 shares of company stock worth $10,595 over the last 90 days. 32.76% of the stock is owned by insiders.

Institutional Investors Weigh In On Tenaya Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Synovus Financial Corp purchased a new stake in shares of Tenaya Therapeutics in the third quarter valued at $28,000. Woodline Partners LP purchased a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at $28,000. Commerce Bank purchased a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at $29,000. Mariner LLC purchased a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at $30,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.